As investors grapple with whether or not to buy the dip, one technician has found a group of stocks that is impervious to the market’s wild swings.» Read More
Stocks erased all of their gains Monday after an early surge due to a better-than-expected manufacturing report. Financials led the decline.
Over the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma. First the bad news.
The Dow shot up more than 100 points Monday after a report showed manufacturing expanded more than expected last month.
Stock futures pointed to a modest rebound ahead of the open Monday after the Dow and the S&P 500 experienced their biggest one-day percentage drops Friday since July 2.
There’s still a week-and-a-half left in the month, but the markets are currently maintaining yet another month of gains.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Dr. Mark Monane, senior biotech analyst at Needham & Co., named some biotech stocks that look attractive.
Stocks surrendered earlier gains and fell modestly on Tuesday largely due to fresh worries that major banks may need to raise more money.
Stocks traded only modestly lower Tuesday, despite concerns that if major banks need to raise more money a financial hurricane may be brewing.
Cramer makes the call on viewers' favorite stocks.
CNBC's "Power Lunch" team asked some of the best and the brightest from America's big financial firms to list the most promising stocks. Strategists from Citigroup, Goldman Sachs, Cowen & Co. and Deutsche Bank offered CNBC their stock picks.
During his lunchtime keynote speech here at the JPMorgan Healthcare Conference JPM Chairman and CEO Jamie Dimon was asked to give his worst-case scenario for the economy. He said that'd be a 1982-type recession lasting about two years and with unemployment "North of 10 percent." Dimon said it would be "Irrational to not be prepared for that."
Will M&A activity boost biotech stocks in 2009?
Drug pricing pressure under a Democratic administration be darned. $75,000. That's not a salary figure. That's the price one biotech analyst says Vertex Pharmaceuticals and its partner Johnson & Johnson might be able to charge--possibly even more--for their Hepatitis C drug.
Plus, Cramer make the call on IBM, CSX, Celgene and more.
This is how you balance Mad Money stock picks with your own portfolio.
This biotech sells its treatment to a niche clientele for big money.
Vertex Pharma is lagging its peers. But biotech is so good right now, it might not matter.
It's a big day for pipeline progress...or not. Late Friday, Merck and Schering-Plough announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.
Schering-Plough beat the Street by a surprising 16 cents per share and the beaten-down shares are rallying. In an exclusive CNBC interview Wednesday morning, Chairman and CEO Fred Hassan explained how the company was able to blow away estimates...